Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 10
Submit an article Journal homepage
359
Views
157
CrossRef citations to date
0
Altmetric
Reviews

New strategies to deliver anticancer drugs to brain tumors

Valentino Laquintana Proffessor, Facoltà di Farmacia, Università degli Studi di Bari, Dipartimento Farmaco Chimico, Via Orabona 4, 70125 Bari, Italy +039 0805442764; +039 0805442754; [email protected]
, PhD,
Adriana Trapani Proffessor, Facoltà di Farmacia, Università degli Studi di Bari, Dipartimento Farmaco Chimico, Via Orabona 4, 70125 Bari, Italy +039 0805442764; +039 0805442754; [email protected]
, PhD,
Nunzio Denora Proffessor, Facoltà di Farmacia, Università degli Studi di Bari, Dipartimento Farmaco Chimico, Via Orabona 4, 70125 Bari, Italy +039 0805442764; +039 0805442754; [email protected]
, PhD,
Fan Wang Temple University, School of Pharmacy, Department of Pharmaceutical Sciences, 3307 North Broad Street, Philadelphia, PA, USA
, PhD,
James M Gallo Temple University, School of Pharmacy, Department of Pharmaceutical Sciences, 3307 North Broad Street, Philadelphia, PA, USA
, PhD &
Giuseppe Trapani Proffessor, Facoltà di Farmacia, Università degli Studi di Bari, Dipartimento Farmaco Chimico, Via Orabona 4, 70125 Bari, Italy +039 0805442764; +039 0805442754; [email protected]
Pages 1017-1032 | Published online: 07 Sep 2009

Bibliography

  • Newton HB. Primary brain tumors: review of etiology, diagnosis and treatment. Am Fam Physician 1994;49:787-97
  • Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther 2001;1:395-401
  • Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. International histological classification of tumours. Geneva, Switzerland, World Health Organization 1995
  • Shai RM, Reichardt JKV, Chen TC. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 2008;4:525-34
  • Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97
  • Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005;109:93-108
  • DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23
  • Brandes AA, Fiorentino MV. The role of chemoterapy in recurrent malignant gliomas: an overview. Cancer Invest 1996;14:551-9
  • Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007;6:1909-19
  • Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncol 2000;2:45-59
  • Huynh GH, Deen DF, Szoka FC Jr. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 2006;110:236-59
  • Sarin H, Kanevsky AS, Wu H, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008;6:80
  • Provenzale JM, Mukundan S, Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. Am J Roentgenol 2005;185:763-7
  • Beduneau A, Saulnier P, Benoit J-P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007;28:4947-67
  • Mathieu D, Fortin D. Chemotherapy and delivery in the treatment of primary brain tumors. Curr Clin Pharmacol 2007;2:197-211
  • Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors part 2:PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004;4:105-28
  • Blakeley J. Drug delivery to brain tumors. Curr Neurol Neurosci Rep 2008;8:235-41
  • Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modification of drugs or drug-nanoparticles? Drug Discov Today 2008;13:1099-106
  • Muldoon LL. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2008;25:2295-305
  • Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 1998;18:1303-12
  • Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytomas. A Medical Research Council Trial. J Clin Oncol 2001;19:509-18
  • Baker SD, Wirth M, Statkevich P. Absorption, metabolism and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999;5:309-17
  • Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive highgrade glioma. Cancer Chemother Pharmacol 1997;40:484-8
  • Stupp R, Mason W, van de Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
  • Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17:2762-71
  • Available from: http:www.cancer.gov/search/ViewClinicalTrials
  • Osoba D, Brada M, Yung WKA, et al. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000;36:1788-95
  • Stupp R. Hegi ME, Gilbert MR, et al. Chemioradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127-36
  • Abbott NJ, Ronnback L, Hansson E, et al. Astrocyte-endothelial interactions at the blood brain barrier. Nat Rev Neurosci 2006;7(1):41-53
  • Lai CH, Kuo KH. The critical component to establish in vitro BBB model: pericyte. Brain Res Rev 2005;50(2):258-65
  • Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967;34(1):207-17
  • Levin VA, Patlak CS, Landahl HD, et al. Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm 1980;8(3):257-96
  • Di L, Kerns EH, Bezar IF, et al. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J Pharm Sci 2009;98(6):1980-91
  • Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol 1999;5(6):556-69
  • Gaillard PJ, Visser CC, de Boer AG, et al. Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv 2005;2(2):299-309
  • Pardridge WM. Blood-brain barrier drug targeting: the future of brain development. Mol Interv 2003;3(2):90-105
  • Hediger MA, Romero MF, Peng JP, et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 2004;447(5):465-8
  • Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 2006;239(2):168-82
  • Ito K, Suzuki H, Horie T, et al. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 2005;22(10):1559-77
  • Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 2002;38(6):339-48
  • Becker I, Becker KF, Meyermann R, et al. The multidrug-resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol 1991;82(6):516-9
  • Gallo JM, Li S, Guo P, et al. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003;63(16):5114-7
  • Sikic BI, Fisher GA, Lum BL, et al. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40(Suppl):S13-9
  • Kemper EM, Boogerd W, Thuis I, et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004;30(5):415-23
  • Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22(47):7537-52
  • Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6(8):591-602
  • Sawada T, Kato Y, Kobayashi M, et al. Immunohistochemical study of tight junction-related protein in neovasculature in astrocytic tumor. Brain Tumor Pathol 2000;17(1):1-6
  • Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 2000;100(3):323-31
  • Levin VA. Pharmacokinetics and central nervous system chemotherapy. New York, McGraw-Hill 1987
  • de Vries NA, Beijnen JH, Boogerd W, et al. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother 2006;6(8):1199-209
  • Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8(8):610-22
  • Zhou O, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 2009;11(3);301-10
  • Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008;14(5):1540-9
  • Haga S, Hinoshita E, Ikezaki K, et al. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 2001;92(2):211-9
  • Rittierodt M, Harada K. Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression–a special role for endothelial cells. Exp Toxicol Pathol 2003;55(1):39-44
  • Gallo JM, Li S, Guo P, et al. The effect of P-glicoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003;63(16):5114-7
  • Regina A, Demeule M, Che C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008;155:185-97
  • Jones AR, Shusta EV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24:1759-71
  • Karkan D, Pfeifer C, Vitalis TZ, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS ONE 2008;3(6):e2469
  • Waldeck W, Wiessler M, Eheman V, et al. TMZ-Bioshuttle – a reformulated temozolomide. Int J Med Sci 2008;5:273-84
  • Bihorel S, Camenisch G, Lemaire M, et al. Pharm Res 2007;24:1720-8
  • Breedveld P, Beijnen JH, Schellens JHM. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006;27:17-24
  • Pilkington GJ, Parker K, Murray SA. Approaches to mitochondrially mediated cancer therapy. Semin Cancer Ther 2008;18:226-35
  • Decaudin D. Peripheral benzodiazepine receptor and its clinical targeting. Anticancer Drugs 2004;15:737-45
  • Guo P, Ma J, Li S, et al. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol 2001;48:169-76
  • Vlodavsky E, Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neurooncol 2007;81:1-7
  • Sekimata K, Hatano K, Ogawa M, et al. Radiosynthesis and in vivo evaluation of N [11C]methylated imidazopyridineacetamides as PET tracers for peripheral benzodiazepine receptors. Nucl Med Biol 2008;35:305-14
  • Omuro A. Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 2008;9:1287-95
  • da Fonseca CO, Linden R, Futuro D, et al. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp 2008;56:267-76
  • Opel D, Westhoff M-A, Bender A, et al. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor– and drug-induced apoptosis. Cancer Res 2008;68:6271-80
  • Nappe A. Drug discovery and development of innovative therapeutics –IBC's 13th Annual World Congress. Approaches to cancer therapy. IDrugs 2008;11:705-9
  • Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas–efficacy and safety issues. Curr Opin Neurol 2008;21:736-44
  • Poulsen HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 2009;48:52-8
  • Sampson JH, Archer GE, Mitchell DA, et al. Tumor specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008;20:267-75
  • Mintz A, Gibo DM, MandhanKumar AB, et al. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha. Cancer Biother Radiopharm 2008;23:581-9
  • Halatsch ME, Schmidt U, Behnke-Mursch J, et al. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006;32:74-89
  • Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68:6043-8
  • Neuwelt EA. Mechanisms of disease: the blood brain barrier. Neurosurgery 2004;54:131-40
  • Vykhodtseva N, McDannold N, Hynynen K. Progress and problems in the application of focused ultrasound for blood–brain barrier disruption. Ultrasonics 2008;48:279-96
  • Jahnke K, Kraemer DF, Knight KR, et al. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer 2008;112:581-8
  • Cao Y, Tsien CI, Shen Z, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005;23:4127-36
  • Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-80
  • Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79-88
  • Vukelja SJ, Anthony SP, Arseneau JC, et al. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 2007;18:283-9
  • Sheleg SV, Korotkevich EA, Zhavrid EA, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002;60:53-9
  • Gururangan S, Cokor L, Rich JN, et al. Phase I study of Gliadel wafer plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol 2001;3:246-50
  • Barth RF, Yang W, Wu G, et al. Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. Proc Natl Acad Sci USA 2008;105:17493-7
  • Rousseau J, Barth RF, Moeschberger M, et al. Efficacy of intracerebral delivery of carboplatin in combination with photon irradiation for treatment of F98 glioma-bearing rats. Int J Radiat Oncol Biol Phys 2009;73:530-6
  • Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005;19:311-30
  • Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318
  • Ogawara K, Furumoto K, Takakura Y, et al. Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. J Control Release 2001;77:191-8
  • Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008;29:487-96
  • Pardridge W. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev 1999;36:299-321
  • Soni V, Kohli D, Jain SK. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 2008;16:73-8
  • Doi A, Kawabata S, Iida K, et al. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 2008;87:287-94
  • Yanagie H, Ogata A, Sugiyama H, et al. Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 2008;5:427-43
  • Gupta B, Levchenko TS, Torchilin VP. TAT Peptide-modified liposomes provide enhanced gene delivery intracranial human brain tumor xenografts in nude mice. Oncol Res 2007;16:351-9
  • Chertok B, David AE, Huang Y, et al. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release 2007;122:315-23
  • van Landeghem FKH, Maier-Hauff K, Jordan A, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 2009;30:52-7
  • Tsutsui Y, Tomizawa K, Nagita M, et al. Development of bionanocapsules targeting brain tumors. J Control Release 2007;122:159-64
  • Schneider T, Becker A, Ringe K, et al. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 2008;195:21-7
  • Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007;59:454-77
  • Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:491-504
  • Brioschi A, Zenga F, Zara GP, et al. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol Res 2007;29:324-30
  • Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008;130:98-106
  • Musacchio T, Laquintana V, Latrofa A, et al. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm 2009;6:468-79
  • Dhanikula RS, Argaw A, Bouchard J-F, et al. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008;5:105-16
  • Zhou Q, Gallo JM. In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J 2005;7:E659-67

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.